KR20140117053A - External composition for improving skin conditions comprising Quercus glauca extracts or methyl gallate or salts thereof - Google Patents

Abstract

The present invention relates to a skin external composition for inhibiting the generation of advanced glycation end products comprising a Quercus glauca extract, methyl gallate, or cosmetically or pharmaceutically acceptable salt thereof as active ingredients. More specifically, the composition of the present invention inhibits the generation of the advanced glycation end products and has an effect on the reduction of skin wrinkles through mechanisms of protecting fibroblasts from damage of cells. Also, the present invention has no cytotoxicity and cutaneous side effects, thereby being applied to a cosmetic or a medicine safely.

Description

[0001] The present invention relates to a composition for external skin glycosylation inhibiting activity, which comprises Quercus glauca extract or methyl gallate or salts thereof as an active ingredient,

The present invention relates to a method for preventing skin wrinkles and improving skin wrinkles by containing a final glycocalylation product inhibitor containing methylgalate or a cosmetically or pharmaceutically acceptable salt thereof and a final glycation endogenesis inhibitor And an external preparation composition.

 Glycation is a nonenzymatic reaction between sugars and proteins that reacts with the carbonyl of the reducing sugar and the free amino group lysine or arginine of the protein to form the schiff base, , And the compounds thus formed are continuously reacted to generate advanced glycation end products (AGEs), which are browning compounds through a series of reactions such as cross-linking.

Specifically, in the normal state, the sugar and the protein undergo a Millard reaction, which is a non-enzymatic reaction to form a schiff base and rearranged to form amadori early glycosylation products The reaction up to here occurs reversibly and its concentration is controlled. However, when the hyperglycemic state persists, the reversible amaryllis type early glycation products are rearranged without degradation, cross-linking with long-lived proteins, resulting in irreversible final glycation products (Ulrich P et al., Recent Prog Horm Res 56; 1-21: 2001). The resulting final glycation products are known to cross-link with extracellular matrix proteins or to react with the final glycated product receptors or nucleic acids of body cells (endothelial cells, smooth muscle, immune cells, etc.) to induce diabetic complications. Therefore, many researches have been conducted to find a pharmacologically active substance which inhibits the glycation reaction that produces the final glycation endproduct to prevent diabetic complications.

In addition, the glycation reaction occurs rapidly in diabetic patients having hyperglycemia, but the glycation reaction occurs in normal persons having normal blood sugar as the aging progresses. Typically, it is known that cross-linking with collagen results in the accumulation of the final glycation products in the skin, which leads to skin elasticity reduction and wrinkles. The half-life of these final glycation products is two times Which is known to induce damage to skin cells such as fibroblasts. In addition, it has been reported that abnormal lipid metabolism occurs during the production of a final saccharide product and oxidative stress is induced due to deterioration of the defensive system function against harmful oxygen free radicals generated at the same time. This is caused by Alzheimer's disease, Aging Medicine, 8 (3) (2001), pp. 183-190, 1986. In the present study, : 23-29, 2011; Reddy VP et al., Neurotox Res 4; 191-209: 2002; Fuentealba D et al., Photochem Photobiol. 85 (1): 185-94, 2009).

In order to prevent diabetes, skin wrinkles, cellular damage, and chronic diseases caused by the final glycation end product, it has been proposed to use carnosine, benfotiamine, pyridoxamine, taurine ), Aminoguanidine, aspirin, and the like. However, aminoguanidine was stopped due to toxicity related to vitamin B deficiency in Phase III clinical trials. In the case of pyridoxamine, the drug has not yet been commercialized as it is currently undergoing phase 2 clinical trials and is in phase 3 preparations.

On the other hand, Quercus glauca Thunb . Is an evergreen tree of oak woody oak, and it is known to be distributed in Japan, China and the Himalayas. The endosomal tree may be selected from the group consisting of Rutin, methylgallate, catechin, epicatechin, gallocatechin, epigallocatechin, procyanidin B- 4), catechin-3-O-rhamnoside, querglanin, isoquerglanin, 1,2,3,6-tetragalauryl glucose ( 1,2,3,6-tetragalloylglucose), 1,2,6-trigalloylglucose, and the like, and in the case of the public, Jaundice, and tumor treatment. In addition, methyl gallate is known to have anti-inflammatory and antimicrobial effects (Chung IM et al., Hum Exp Toxicol 30 (9): 1415-1419, 2011; Sheu SY et al., Am J Chin Med. Fang SH et al., J Ethnopharmacol. 5: 116 (2): 333 (1994), pp. 307-315, 1997; Yang HJ et al., J. Soc. Cosmet Scientists Korea 34: -340, 2008).

Korean Patent No. 1156857 discloses a preservative composition impregnated with a component of an oak plant, and Korean Patent Publication No. 2008-0097314 discloses a composition containing a plant extract of an oak plant Korean Patent No. 0976927 discloses an antimicrobial composition for inhibiting salmonella containing a ciprofloxacin, which is a conventional antibiotic, by separating methyl gallate, which is a natural antimicrobial agent, from a dwarf .

However, as yet to the present invention, the effect on the inhibition of the production of the final glycation end product by the extract or the methyl gallate is not disclosed.

Accordingly, the present inventors have made efforts to develop a composition for external application for skin which is harmless to the human body and has excellent safety but also has an effect of inhibiting the final glycation end product, and as a result, the present invention has been completed.

One object of the present invention is to provide a composition for preventing external glycation end products which comprises Quercus glauca extract or methylgallate or a cosmetic or pharmaceutically acceptable salt thereof as an active ingredient .

Another object of the present invention is to provide a cosmetic composition for inhibiting the production of a final glycation end product comprising Quercus glauca extract, or methylgallate or a cosmetically acceptable salt thereof as an active ingredient will be.

Another object of the present invention is to provide a pharmaceutical composition for inhibiting the production of a final glycation end product comprising Quercus glauca extract or methylgallate or a pharmaceutically acceptable salt thereof as an active ingredient .

In one aspect of the present invention, the present invention provides a method for inhibiting the production of a final glycation end product comprising Quercus glauca extract, or methylgallate or a cosmetic or pharmaceutically acceptable salt thereof as an active ingredient, Skin external composition for skin.

In the present invention, it is preferred that the seedling extract is any one or more selected from the group consisting of perilla, flesh, fruit, seeds, leaves, stems, branches and roots, And more preferably one or more selected from the group consisting of leaves and branches can be extracted and used.

In the present invention, it is possible to use a water extract, an anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, Butanol, etc.), a mixed solvent of the lower alcohol and water, acetone, ethyl acetate, chloroform, hexane or 1,3-butylene glycol as an extraction solvent.

In addition to the method of extracting with the above-mentioned extracting solvent, the above-mentioned Jonggakseong extract can be extracted by methods such as ultrasonic extraction, ultra-high pressure extraction, cold extraction, filtration extraction, hot water extraction and reflux cooling extraction. Can also be obtained through a phosphorylation process. For example, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatographies (made for separation by size, charge, hydrophobicity or affinity) The obtained fractions can also be obtained.

In the present invention, the extract of Pinus rigida contains all the extract, fraction and purified product obtained in each step of extraction, fractionation or purification, their diluted solution, concentrate or dried product.

In the present invention, the methylgallate is a methyl-3,4,5-trihydroxybenzoic acid (gallic acid) having a structure represented by the following general formula , And is one of the phenolic compounds of the seedling.

The methyl gallate can be extracted, separated and purified from Quercus glauca or obtained by culturing microorganisms such as Saccharomyces cerevisiae or chemically synthesized products (for example, Methyl 3,4,5-trityroxybenzoate of Sigma).

In the present invention, the cosmetically or pharmaceutically acceptable salts of the above-mentioned methyl gallate include metal salts formed by acid addition salts or bases formed by cosmetically or pharmaceutically acceptable free acids useful. As an example of the free acid, inorganic acids and organic acids can be used. As the inorganic acids, hydrochloric acid, sulfuric acid, bromic acid, sulfurous acid, or phosphoric acid can be used. Examples of the organic acids include citric acid, acetic acid, maleic acid, fumaric acid, Sulfonic acid and the like can be used. As the metal salt, an alkali metal salt or an alkaline earth metal salt, sodium, potassium or calcium salt may be used. But is not necessarily limited thereto.

In the present invention, the inhibition of the final glycation endproduct formation is characterized by the inhibition of ultimate glycation end products which can inhibit the glycation reaction of skin cells, particularly dermal fibroblast cells.

In the present invention, inhibition of final glycation endogenesis refers to inducing improvement of at least one skin condition selected from skin wrinkle improvement, skin elasticity improvement, aging prevention, and skin regeneration.

According to the present invention, the composition for external application for skin glycosylation inhibition, which comprises the above-mentioned clathrate extract, or methyl gallate or a cosmetic or pharmaceutically acceptable salt thereof as an active ingredient, inhibits the production of ultimate glycosylation products of the skin, Protects cells damaged by glycation products, thereby exhibiting excellent skin wrinkles, skin elasticity, anti-aging, and skin regeneration.

In one specific embodiment, the cell survival rate of glycosylation of G. hirsuta extract and methyl gallate using human normal fibroblast was examined. As a result, And the survival rate of the cells was higher than that of the damaged cells. Therefore, it was confirmed that the extracts and methyl gallate of the seedlings were effective in inhibiting the cell damage from the final glycation end product stress.

In another specific embodiment, skin elasticity was examined using a cosmetic composition containing the extract of Pinus rigida or methyl gallate on the human skin. As a result, the skin elasticity of the cosmetic composition containing the Pinus rigorus extract or methyl gallate was evaluated as follows: It was confirmed that the extracts and methyl gallate of Seonggakshi tree had the effect of improving the wrinkles.

In the present invention, it is preferable that the above-mentioned seedling tree extract, or methyl gallate or a cosmetic or pharmaceutically acceptable salt thereof is used in an amount of 0.00001 to 15% by weight, preferably 0.0001 to 10% by weight, By weight, and 0.001 to 5% by weight. When the weight of the extract or the methyl gallate or the cosmetic or pharmaceutically acceptable salt thereof is less than 0.0001% by weight, the effect of inhibiting the final glycosylation is too weak, and when it exceeds 15% by weight, There is a problem in that the increase in the effect due to an increase in the content of methyl gallate or its cosmetically or pharmaceutically acceptable salt is insufficient.

In the present invention, the composition can be used as a cosmetic composition for external skin application for inhibiting ultimate glycation products, which comprises an extract of Japanese cypress tree or methyl gallate or a cosmetically acceptable salt thereof as an active ingredient.

The contents and efficacy of the extract of the present invention or the extract of methyl gallate or a cosmetically acceptable salt thereof are as described above.

The cosmetic composition according to the present invention may further comprise components commonly used in cosmetic compositions, in addition to the composition for inhibiting the final glycation endproduct containing the extract of the present invention, or a methyl gallate or a cosmetically acceptable salt thereof as an active ingredient have. For example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavoring agents, and carriers may be included.

The cosmetic composition may be prepared in any form conventionally produced in the art and may be in the form of, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant- , A powder foundation, an emulsion foundation, a wax foundation, and a spray, but the present invention is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.

When the formulation of the cosmetic composition is a paste, a cream or a gel, the carrier component may be an animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide Can be used.

When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of spray, a mixture of chlorofluorohydrocarbons, Propellants such as propane / butane or dimethyl ether.

In the case of the solution or emulsion of the cosmetic composition, a solvent, a solubilizer or an emulsifier is used as a carrier component. Examples of the solvent include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butylene glycol, a glycerol aliphatic ester, a polyethylene glycol, or a fatty acid ester of sorbitan can be used as a solubilizing agent or an emulsifying agent.

When the formulation of the cosmetic composition is in the form of a suspension, the carrier component may be a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tragacanth gum may be used.

When the formulation of the cosmetic composition is an interfacial active agent-containing cleansing agent, it is preferable to use, as carrier components, aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyltaurate, sarcosinates, fatty acids Amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

Or the pharmaceutically acceptable salt thereof is 0.00001 to 15% by weight, preferably 0.0001 to 10% by weight, more preferably 0.001 to 5% by weight, based on the total weight of the total composition. As the content. When the weight of the extract is less than 0.0001% by weight, the effect of inhibiting the final glycosylation is too weak. When the weight of the extract is more than 15% by weight, There is a problem that the increase in the effect due to an increase in the content of the salt or the cosmetically acceptable salt thereof is insufficient.

In the present invention, the composition can be used as a composition for external dermal application for inhibiting ultimate glycation products, which comprises an extract of Japanese cypress tree or methyl gallate or a pharmaceutically acceptable salt thereof as an active ingredient.

The contents and efficacy of the extract of the present invention, methylgalate or a pharmaceutically acceptable salt thereof, and the like are as described above.

The pharmaceutical composition according to the present invention may additionally contain components commonly used in pharmaceutical compositions in addition to the composition for inhibiting the final glycation endproduct containing the extract of the present invention or the methylgalate or a pharmaceutically acceptable salt thereof as an active ingredient have. For example, lubricants, wetting agents, sweeteners, flavoring agents, emulsifying agents, suspending agents, preservatives and carriers.

Suitable carriers for such pharmaceutical compositions include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, Syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, but are not limited thereto. Carriers and preparations which are acceptable as suitable medicaments are described in detail, for example, in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition may be applied to mammals such as rats, mice, livestock, humans, etc. by oral or parenteral administration, and is preferably administered by parenteral administration, more preferably topical application by application .

The pharmaceutical composition is administered in a medically effective amount. A therapeutically effective amount in the present invention means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention. The effective dose level will depend on the type of disease and its severity, the activity of the drug, Including the age, weight, health and sex of the patient, sensitivity of the patient to the drug, time of administration of the particular extract used, route of administration and rate of release, duration of treatment, Can be determined according to factors well known in the art. Generally, a dose of 0.001 to 100 mg / kg, preferably 10 to 100 mg / kg on an adult basis can be administered once to several times per day. When the composition is an external preparation, it is preferable to apply the composition in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day and continue for 1 month or more. However, the scope of the present invention is not limited by the dose.

The pharmaceutical composition may be prepared in a unit dosage form by formulating it together with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person skilled in the art to which the present invention belongs, Into the container. The formulations may be formulated into tablets, capsules, powders, granules, suspensions, emulsions, syrups, emulsions, alerts, ointments, sprayers, oils A tablet, a tincture, a bath, a liniment, a lotion, a patch, a pad, a cream, and the like. In addition, it can be preferably used as an external preparation for skin intended for topical administration for application directly to the affected area. In this case, a form such as an ointment, a lotion, a spray or a gel is preferable. These external preparations for skin may also be included in a support base or matrix or the like, which can be applied directly to the treatment site, and examples of the support substrate include gauze or bandages.

The above-mentioned seedling tree extract, or methyl gallate or a pharmaceutically acceptable salt thereof is used in an amount of 0.00001 to 15% by weight, preferably 0.0001 to 10% by weight, more preferably 0.001 to 5% by weight As the content. When the weight of the extract is less than 0.0001% by weight, the effect of inhibiting the final glycosylation is too weak. When the weight of the extract is more than 15% by weight, There is a problem in that the increase in the effect due to the increase in the amount of the salt or the pharmaceutically acceptable salt is insufficient.

The composition for external application for skin inhibiting the final glycation endproduct comprising the inventive conjugate tree extract or methyl gallate or a cosmetic or pharmaceutically acceptable salt thereof as an active ingredient inhibits the production of the final glycation products, It has the effects of improving wrinkles of skin, improving skin elasticity, preventing skin aging, and regenerating skin through inhibiting the production of glycation products. And can be safely applied to cosmetics or medicines without cytotoxicity and skin side effects.

FIG. 1 shows the results of measuring the inhibitory effect of the present glycyrrhiza extract and methyl gallate on the final glycation end product.
FIG. 2 shows the results of measuring the fibroblast-protecting effect from the glycosylation stress of the extract of the present invention and methyl gallate.

Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for describing the present invention more specifically, and the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention.

Example 1: Manufacture of Conidia japonica extract

The fruit and branches of the seedlings were picked and washed thoroughly to remove the impurities and impurities completely, shaken at 20 to 35 ° C respectively, and pulverized to have a size of 1 mm or less. Then, 1 kg of the pulverized seedlings and eggplant powder were immersed in 5 L of 95% ethanol and sonicated for 24 hours. Thereafter, the obtained extract was filtered through a filter paper (Advantes, No. 2) and concentrated under reduced pressure to prepare a crude myrtle extract.

Example 2: Isolation of methyl gallate from a seedling tree

 After 30 g of the extract obtained in Example 1 was suspended in 300 ml of water, the same amount of hexane was added and sonication was performed for 24 hours. The same operation was repeated three times and then concentrated under reduced pressure to obtain 10 g of a hexane fraction. After the fraction was separated, 300 ml of chloroform was added, and the mixture was sonicated and concentrated under reduced pressure to obtain 18 g of a chloroform fraction. After the chloroform fraction, The mixture was repeatedly extracted three times, and then concentrated under reduced pressure to obtain 20 g of an ethyl acetate fraction. The remaining suspension after the fractionation with ethyl acetate was added with 300 ml of butanol, and the mixture was repeated three times, and then concentrated under reduced pressure to obtain 17 g of a butanol fraction and a purified water layer.

The solvent-extracted fractions were subjected to column chromatography as follows to obtain methyl gallate. First, the ethyl acetate fraction was applied to a silica column (5 × 35 cm, FUJI silica gel, Tokyo, Japan) and eluted with chloroform, 50% methanol-water and water to obtain 12 small fractions. Small fraction 3 of these small fractions was again subjected to medium pressure liquid chromatography (Redisep Rf silica 80 g flash column, Teledyne ISCO, USA) and eluted with chloroform / methanol (7: 3, v / v) 10 small fractions were obtained and small fractions 1 and 2 of these small fractions were separated by preparative HPLC (Pehnomenex Luna C18 100A column, 250 x) with acetone / water (3: 7, v / v) 30 mm) was carried out to obtain 22 mg of methyl gallate.

Example 3: Measurement of inhibitory effect on the production of ultimate glycation products of the extracts of methylene chloride and methyl gallate

A glycation inhibitor assay was performed to determine the inhibitory activity of the final glycosylation products of the extract of the seedlings produced in Example 1 and the methyl gallate isolated in Example 2. Specifically, bovine serum albumin (BSA) was selected as a protein source. BSA was added to 0.1 M phosphate buffer (pH 7.0) to a concentration of 1 mg / ml. Glucose was used as a source of glucose and it was added to 0.1 M phosphate buffer (pH 7.0) so that the concentration of glucose was 200 mM. BSA and glucose were then added to the 1.5 ml microcube. Then, the mixture of BSA and glucose was treated with 100 and 500 ppm of the seedling extract or 100 and 500 ppm of methyl gallate, completely sealed, and then cultured in a constant temperature and constant humidity incubator at 60 ° C for 2 days. After the incubation, 50 쨉 l of 100% (w / v) trichloroacetic acid (TCA) was treated, left at 4 째 C for 30 minutes, and centrifuged at 15,000 rpm. After centrifugation, the supernatant was removed and 0.5 ml of PBS (Phosphate buffered saline, pH 10) was added to dissolve the precipitate. The dissolved precipitate was transferred to a 96-well fluorescent microplate and measured at 370 nm excitation wavelength and 440 nm emission wavelength using a spectrofluorometer (INFINITE M200, Tecan, Switzerland). The control group was a mixture of BSA and glucose, and the positive control group was aminoguanidine. The results are shown in Fig.

As a result of the experiment, it was confirmed that the extracts and the methyl gallate inhibited the production of the final glycation end product.

Example 4: Protective effect of fibroblast from glycation stress

Human normal fibroblasts were inoculated into 24-well microplates containing DMEM medium to a concentration of about 3 x 10 ⁴ cells, and cultured in a 5% CO ₂ incubator at 37 ° C for 24 hours Lt; / RTI > Then, the medium of each well was exchanged with glucose-free 5% serum DMEM medium, and glucose (200 mM), which is capable of inducing glycosylation stress, and 50 / / ml of methylene chloride extract or 10 / / ml and then cultured for 72 hours. Cell viability was measured using MTT assay (ATCC ^TM , 30-1010K) at the end of culture. Cellular regeneration was also calculated using Equation 1. Glucose was used as the control group, and aminoguanidine was used as the positive control group. The results are shown in Table 1 and Fig.

[Experimental Equation 1]

Measurement of cell regeneration rate = {(sample treatment group - glucose treated group) / (glucose treated group)} x 100

Test Items Example 1
(50 [mu] g / ml) Example 2
(10 [mu] g / ml) Cell regeneration rate 61 46

As shown in the above Table 1, it was confirmed that the extracts and the methyl gallate of Zygomyx sinensis have an effect of regenerating cells of the fibroblasts induced by glucose.

Also, as shown in FIG. 2, it was shown that the extracts of Mulberry seeds and methyl gallate inhibited the cell death of fibroblasts induced by glycosylation stress by high glucose.

Example 5: Measurement of the wrinkle-improving effect of a cosmetic composition containing a methylene chloride extract or methyl gallate

5-1. Manufacture of Cream containing Jonggashimok tree extract or methyl gallate

A nutritional cream containing a seedling extract or methyl gallate having the components and contents as shown in the following Tables 2 and 3 was prepared. Specifically, the water-purifying water, triethanolamine and propylene glycol were heated and dissolved at 70 DEG C, and then a fatty acid, an oily component, an emulsifier and an antiseptic agent were heated to 70 DEG C to dissolve. After the emulsification was completed, the solution was cooled to 45 캜 and 0.1% by weight of wood extract or methyl gallate was added thereto and dispersed, followed by cooling to 30 캜.

ingredient Content (% by weight) Jonggashu tree extract (fruit or eggplant) 0.1 Jojoba oil 5.0 Liquid paraffin 7.0 Cetylaryl alcohol 2.0 Polyglyceryl-3 methylglucose distearate 2.0 Glyceryl stearate 0.5 Squalane 3.0 Propylene glycol 4.0 glycerin 5.0 Triethanolamine 0.3 Carboxyvinyl polymer 0.3 Tocopheryl acetate 0.2 Preservative, incense a very small amount Purified water Balance Sum 100

ingredient Content (% by weight) Methyl gallate 0.1 Jojoba oil 5.0 Liquid paraffin 7.0 Cetylaryl alcohol 2.0 Polyglyceryl-3 methylglucose distearate 2.0 Glyceryl stearate 0.5 Squalane 3.0 Propylene glycol 4.0 glycerin 5.0 Triethanolamine 0.3 Carboxyvinyl polymer 0.3 Tocopheryl acetate 0.2 Preservative, incense a very small amount Purified water Balance Sum 100

5-2. Measurement of wrinkle-improving effect of nutritional cream containing Jongga-ga tree extract or methyl gallate

15 healthy female women aged 26 to 40 years were divided into two groups, one twice a day for three months, and the other group, Respectively. As a control group, nutritional creams prepared by adding Jangga seed tree extract or purified water instead of methyl gallate were used.

The wrinkle improvement effect was evaluated by measurement of skin elasticity change, and skin elasticity was measured with a Cutometer SEM 474 (Courage + Khazaka, Cologne, Germany) under the condition that the temperature was maintained at 24 to 26 ° C and the humidity was constant at 38 to 40% . The comparison criteria were as follows: 0 for no skin elasticity, 5 for many cases. The results are shown in Table 4.

Example 1 Example 2 Control group Skin elasticity 2.81 2.73 2.40

As shown in Table 4 above, when the nutritional cream containing the extract of the present invention or methyl gallate is used, the skin elasticity is increased as compared with the case of using the nutritional cream without the seed extract or methyl gallate , And that the extracts of P. japonica were more effective than those of methyl gallate.

Example 6: Test for confirming safety of human ginseng extract or methyl gallate on human skin

6-1. Preparation of external preparations for skin, including Jonggasi extract or methyl gallate

In order to confirm that the extracts of Jonggaegi-mushroom or methyl gallate are safe for the human skin, a skin external preparation containing 1% by weight of the extract or methyl gallate was prepared according to the ingredients and contents of the following Table 5, Respectively. First, squalene was mixed with purified water, glycerin, and butylene glycol, and dissolved at a temperature of about 70 DEG C (water part). Then, the three components and the other components except for trimethanolamine were dissolved at a temperature of about 70 DEG C Part). Thereafter, the oil part was added to the water-based part, and the mixture was firstly emulsified with a homomixer (Tokushu Kika, Japan), followed by final addition of trimethanolamine.

ingredient content (%) Test group 1 Test group 2 Control group Purified water 71 71 71 glycerin 8.0 8.0 8.0 Butylene glycol 4.0 4.0 4.0 Jonggashu tree extract 0.1 0 0 Methyl gallate 0 0.1 0 Caprylic Capri Triglyceride 8.0 8.0 8.0 Squalane 5.0 5.0 5.0 Cetearyl glucide 1.5 1.5 1.5 Sorbitan stearate 0.4 0.4 0.4 Cetearyl alcohol 1.0 1.0 1.0 Trimethanolamine 0.1 0.1 0.1 Gross weight 100 100 100

6-2. Experiment of cumulative stimulation of skin

The skin external preparation prepared by the method of 6-1 was applied to a healthy 30 adults for 9 times for 24 hours cumulative epidermal patches on the upper forearm every day to determine whether or not the skin extract or methyl gallate stimulates the skin Respectively. As a control group, squalane base was used as an external preparation for skin without vinegar extract.

A pin chamber (Finn chamber, Epitest Ltd, Finland) was used as a pellet, and 15 占 퐇 of each of the skin external preparations was dripped into the chamber and pelletized. The degree of the skin reaction on each occasion was scored using Equation 2 below, and the results are shown in Table 6 below.

[Experimental Equation 2]

Average response rate = [[Reaction index × reaction rate / total number of subjects × highest score (4 points)] × 100] / number of tests

At this time, a score of ± is given as 1, a score of 2 is given as +, and a score of 4 is given as ++, and a safe composition is determined when the average degree of reaction is less than 3.

Test substance Number of subjects who responded (persons) Average
Reactivity 1 week 2 weeks 3 weeks Primary Secondary Third Fourth 5th 6th Seventh 8th car 9th ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ Control group 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0.00 Test group 1 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0.00 Test group 2 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0.00

As shown in Table 6, the number of persons corresponding to ±, +, and ++ in the control group and the test groups 1 and 2 was 0, 0, and 0, respectively, and no skin reaction was observed. As a result of calculation according to the above-described laboratory 1, the average degree of reactivity was 0.00, 0.00 and 0.00, respectively, indicating that the composition was safe.

Production Example 1: Cosmetic preparation

1-1. Production of flexible lotion

As shown in the following Table 7, a flexible lotion containing an extract of Pinus rigida or methyl gallate as an active ingredient was prepared by a conventional method.

ingredient Content (% by weight) The extracts of Zygomucosa juncea or methyl gallate 0.1 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 ethanol 10.0 Triethanolamine 0.1 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

1-2. Manufacture of nutrition lotion

As shown in the following Table 8, a nutritional lotion containing an extract of Pinus rigida or methyl gallate as an active ingredient was prepared by a conventional method.

ingredient Content (% by weight) The extracts of Zygomucosa juncea or methyl gallate 0.1 Wax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 5.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

1-3. Manufacture of nutrition cream

As shown in the following Table 9, a nutritional cream containing an endosperm shark extract or methyl gallate as an active ingredient was prepared according to a conventional method.

ingredient Content (% by weight) The extracts of Zygomucosa juncea or methyl gallate 0.1 Wax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 10.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

1-4. Manufacture of massage cream

As shown in Table 10 below, a massage cream containing an extract of Pinus rigida or methyl gallate as an active ingredient was prepared by a conventional method.

ingredient Content (% by weight) The extracts of Zygomucosa juncea or methyl gallate 0.1 Wax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

1-5. Manufacture of packs

Packs containing the seedling extract or methyl gallate as an active ingredient were prepared according to a conventional method as shown in Table 11 below.

ingredient Content (% by weight) The extracts of Zygomucosa juncea or methyl gallate 0.1 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 Allantoin 0.1 ethanol 5.0 Nonyl phenyl ether 0.3 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

Claims (7)

A composition for external application for skin, which contains Quercus glauca extract, or methylgallate, or a cosmetic or pharmaceutically acceptable salt thereof as an active ingredient, for inhibiting ultimate glycation products (AGEs).
The method according to claim 1, wherein the Quercus glauca extract is extracted from at least one selected from the group consisting of perilla, flesh, seeds, fruit, leaves, stem, Wherein the external preparation is a skin composition.
The composition for external application for skin according to claim 1, wherein the inhibition of the final glycosylation is performed in fibroblasts of the skin.
The composition for external application for skin according to claim 1, wherein the inhibition of the final glycosylation induces one or more skin conditions selected from the group consisting of skin wrinkle improvement, skin elasticity improvement, aging prevention and skin regeneration.
The composition for external application for skin according to claim 1, wherein the composition is used as a cosmetic or pharmaceutical product.
The cosmetic composition according to claim 5, wherein the cosmetic composition is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing agent, oil, powder foundation, Wherein the composition is in any one form selected from the group consisting of:
7. The method according to any one of claims 1 to 6, wherein the Quercus glauca extract, or Methylgallate, or a cosmetic / pharmaceutically acceptable salt thereof, In an amount of 0.0001 to 15% by weight based on the total weight of the composition.

Images